Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.67.

Several equities research analysts have recently weighed in on the company. BTIG Research reissued a “buy” rating on shares of Innate Pharma in a research report on Thursday, November 5th. UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. HC Wainwright reissued a “buy” rating on shares of Innate Pharma in a report on Monday, September 21st. Leerink Partners downgraded shares of Innate Pharma from an “outperform” rating to a “market perform” rating and set a $1.00 price objective for the company. in a research report on Thursday. Finally, Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday, August 11th.

View Our Latest Research Report on Innate Pharma

Innate Pharma Stock Performance

Innate Pharma stock opened at $0.86 on Thursday. Innate Pharma has a 1-year low of $0.83 and a 1-year high of $2.71. The stock’s fifty day moving average is $1.53 and its two-hundred day moving average is $1.68.

Innate Pharma Company Profile

(Get Free Report)

Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells. The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.

See Also

Analyst Recommendations for Innate Pharma (NASDAQ:IPHA)

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.